<SEC-DOCUMENT>0001437749-21-002671.txt : 20210212
<SEC-HEADER>0001437749-21-002671.hdr.sgml : 20210212
<ACCEPTANCE-DATETIME>20210211215648
ACCESSION NUMBER:		0001437749-21-002671
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210212
DATE AS OF CHANGE:		20210211

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-249057
		FILM NUMBER:		21622373

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>dffn20210211b_fwp.htm
<DESCRIPTION>FORM FWP
<TEXT>
<html><head>
	<title>dffn20210211b_fwp.htm</title>

	<!-- Generated by ThunderDome Portal - 2/12/2021 2:34:11 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"><img alt="logo02.gif" src="logo02.gif"></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Free Writing Prospectus dated February 11, 2021</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Filed pursuant to Rule 433</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Relating to the Preliminary Prospectus Supplement dated February 11, 2021</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Registration Statement&nbsp;No.&nbsp;333-249057</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Free Writing Prospectus</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) has filed a registration statement on Form S-3 (including a prospectus) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) for the offering to which this communication relates. Before you invest, you should read the&nbsp;prospectus&nbsp;in that&nbsp;registration statement, the preliminary&nbsp;prospectus supplement&nbsp;dated February 11, 2021, the information incorporated therein by reference, and the other documents the Company has filed with the SEC for more complete information about the Company and the offering.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The information in this free writing prospectus supplements the preliminary&nbsp;prospectus supplement&nbsp;dated February&nbsp;11, 2021, as follows:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:left;"><b>D</b><b>IFFUSION PHARMACEUTICALS </b><b>INCREASES PREVIOUSLY </b><b>ANNOUNCE</b><b>D </b><b>BOUGHT DEAL OFFERING OF COMMON STOCK</b><b> TO $</b><b>30</b><b> MILLION</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">CHARLOTTESVILLE, Va., February 11, 2021 --&nbsp;<b>Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)</b>&nbsp;(&#8220;Diffusion&#8221; or the &#8220;Company&#8221;), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 17, 2021, subject to satisfaction of customary closing conditions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">H.C. Wainwright &amp; Co. is acting as the sole book-running manager for the offering.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company also has granted to the underwriter a 30-day option to purchase up to an additional 4,390,244 shares of common stock at the public offering price, less underwriting discounts and commission.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The gross proceeds of the offering are expected to be approximately $30,000,000, before deducting underwriting discounts and commissions and offering expenses payable by Diffusion and assuming no exercise of the option to purchase additional shares. Diffusion intends to use the net proceeds of the offering to fund research and development of our lead product candidate, TSC, including the TCOM Study, the DLCO Study, and other clinical trial activities, and for general corporate purposes.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><img alt="logo02.gif" src="logo02.gif"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The shares of common stock described above are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-249057) filed with the Securities and Exchange Commission (SEC) and declared effective on October 2, 2020 and the accompanying prospectus contained therein. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to this offering were filed with the SEC and are available on the SEC's website at&nbsp;<u>www.sec.gov</u>. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, and the final prospectus supplement and the accompanying prospectus relating to this offering when filed, may also be obtained by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail at&nbsp;<u>placements@hcwco.com</u>&nbsp;or by calling 646-975-6996.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">This announcement is neither an offer to sell, nor a solicitation of an offer to buy, any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale is unlawful.&nbsp;Any offer, if at all, will be made only by means of the prospectus forming a part of the effective registration statement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>About Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to the areas where it is needed most. Diffusion&#8217;s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion&#8217;s product candidate DFN-529, a novel PI3K/Akt/mTOR pathway inhibitor, is in early-stage development. For more information, please visit us at www.diffusionpharma.com.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Forward-Looking Statements</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the anticipated timing, size, pricing, and closing of the offering. The Company may, in some cases, use terms such as &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;anticipates&#8221;, &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;intends&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;might&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;approximately&#8221;, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control, and as a result the Company&#8217;s actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risk and uncertainties include, among other things, those related to: market and other conditions, the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the public offering; the Company&#8217;s ability to design, initiate, execute, and complete its ongoing and planned studies evaluating TSC; the Company&#8217;s ability to obtain additional financing; the Company&#8217;s ability to develop and commercialize TSC or any other product candidate; the ongoing COVID-19 pandemic; general economic, political, business, industry, and market conditions; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule, or regulation, the Company undertakes no obligation to update any such statements after the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u><b>C</b></u><u><b>ontacts</b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Investors:&nbsp;</b><br>
Tiberend Strategic Advisors, Inc.&nbsp;<br>
Maureen McEnroe, CFA/Miriam Weber Miller<br>
(212)&nbsp;375-2664/ (212) 375-2694&nbsp;<br>
mmcenroe@tiberend.com/mmiller@tiberend.com</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Media:&nbsp;</b><br>
Jeffrey Freedman<br>
RooneyPartners&nbsp;<br>
(646) 432-0191<br>
jfreedman@rooneyco.com&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo02.gif
<TEXT>
begin 644 logo02.gif
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MJWGCZJ#ZZJ@WN4,.D9"*Q OZMB"-0$11PT+MI 2PWBSNI+!C#<?EL((JO@>
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M0 EP<Q;[-P9"H I;D11F\ W=]0@_T :_APU9, ;G &.K$ MK$ ;I< ,V8 -
M, ;2L"@"(0U$, 9CD 77$ !PP I&!CT3  $.(  "\  >T %8P()(L0<"00$.
M0 "0]%>KL GBD 0(:&?SM0K:4(%&8 3W UD/ 0=>4 9<DB(M\A$+.!!Q  S
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M#IK0#3[P V00#U+P#?&0!+#C4<% "=U@5F"0%,7 #^QP#>$PE:5P#]]P#5;
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M#ZQ@!E>@#^Q2"5%P# %@!KZ@">OP"+S8"DQ0&.#0D+5P"0"099$0#[&P"K(
M -.$#  @#K@A#*V@#E70"K 0#U$0'=W  E%;+K2P F- $&H  ,D0 )%JKLWP
MH % #OS 8X.0"ZT #MS@$48*DTE" R1E!OL@7<,0 _30#DE !0T*!#, (MK
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87,56?,58G,5:O,5<W,5>_,5@/!,! 0 [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
